Patent: 10,279,035
✉ Email this page to a colleague
Summary for Patent: 10,279,035
| Title: | Nanoparticle complexes of paclitaxel, trastuzumab, and albumin |
| Abstract: | This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof. |
| Inventor(s): | Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN) |
| Assignee: | Mayo Foundation for Medical Education and Research (Rochester, MN) |
| Application Number: | 15/412,536 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,279,035
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-10-01 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-10-01 |
| Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2032-10-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
